Matthias Renner is Head of Section `Quality of Coagulation Factors and Gene Therapy´ in the Department of Hematology, Cell and Gene Therapy and Senior Scientific Assessor for quality of Gene Therapy Medicinal Products (GTMPs) at the Paul-Ehrlich-Institut (PEI). In his work Matthias is involved in the evaluation of clinical trial applications and national scientific advice procedures for GTMPs and serves also as scientific consultant in GMP-inspections. Since 2009 he is expert to the European Medicines Agency (EMA) for the assessment of marketing authorisation applications, for scientific advices and other EMA procedures.

He is Member of the EDQM Gene Therapy Working Group and of the Cell and Gene Therapy Committee of the International Alliance for Biological Standardization. From 2016 to 2022, Matthias was German Alternate to the CHMP Biologics Working Party. Since 2010 he was also Member of the EMA CAT Gene Therapy Working Party, and its vice chair since 2011.

Until he joined the PEI, he worked in several positions on the development of cell and gene therapies in the biotech industry. Matthias holds a Ph.D. and a lecturer´s degree in Virology.